keyword
MENU ▼
Read by QxMD icon Read
search

relapse malaria

keyword
https://www.readbyqxmd.com/read/29141719/chloroquine-primaquine-versus-chloroquine-alone-to-treat-vivax-malaria-in-afghanistan-an-open-randomized-superiority-trial
#1
Ghulam Rahim Awab, Mallika Imwong, Germana Bancone, Atthanee Jeeyapant, Nicholas P J Day, Nicholas J White, Charles J Woodrow
Afghanistan's national guidelines recommend primaquine (PQ) for radical treatment of Plasmodium vivax malaria, but this is rarely implemented because of concerns over potential hemolysis in patients who have G6PD deficiency. Between August 2009 and February 2014, we conducted an open-label, randomized controlled trial of chloroquine (CQ) alone versus chloroquine plus primaquine (0.25 mg base/kg/day for 14 days) (CQ+PQ) in patients aged 6 months and older with microscopy confirmed P. vivax infection. In the CQ+PQ group, G6PD deficiency was excluded by fluorescent spot testing...
October 30, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29121061/a-randomized-double-blind-active-control-trial-to-evaluate-the-efficacy-and-safety-of-a-three-day-course-of-tafenoquine-monotherapy-for-the-treatment-of-plasmodium-vivax-malaria
#2
Mark M Fukuda, Srivicha Krudsood, Khadeeja Mohamed, Justin A Green, Sukhuma Warrasak, Harald Noedl, Ataya Euswas, Mali Ittiverakul, Nillawan Buathong, Sabaithip Sriwichai, R Scott Miller, Colin Ohrt
BACKGROUND: Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen. METHODS: This randomized, active-control, double-blind trial was conducted in Bangkok, Thailand. Seventy patients with microscopically confirmed P. vivax were randomized (2:1) to tafenoquine 400 mg once daily for 3 days or 2500 mg total dose chloroquine phosphate (1500 mg chloroquine base) given over 3 days plus primaquine 15 mg daily for 14 days...
2017: PloS One
https://www.readbyqxmd.com/read/29097646/safety-of-weekly-primaquine-in-g6pd-deficient-patient-with-relapsing-vivax-malaria-a-case-report
#3
Deepali Savargaonkar, Md Zohaib Ahmed, Anupkumar R Anvikar, Neena Valecha
No abstract text is available yet for this article.
July 2017: Journal of Vector Borne Diseases
https://www.readbyqxmd.com/read/29082022/systematic-review-of-the-clinical-manifestations-of-glucose-6-phosphate-dehydrogenase-deficiency-in-the-greater-mekong-subregion-implications-for-malaria-elimination-and-beyond
#4
Ken Ing Cherng Ong, Hodaka Kosugi, Sophea Thoeun, Hitomi Araki, Moe Moe Thandar, Moritoshi Iwagami, Bouasy Hongvanthong, Paul T Brey, Shigeyuki Kano, Masamine Jimba
INTRODUCTION: To achieve malaria elimination in the Greater Mekong Subregion (GMS) by 2030, proper case management is necessary. 8-aminoquinolines, such as primaquine, are the only available medicines effective in preventing relapse of the hypnozoite stage of Plasmodium vivax, as well as the onward transmission of Plasmodium falciparum. However, primaquine can cause haemolysis in individuals who have glucose-6-phosphate dehydrogenase deficiency (G6PDd). We conducted a systematic review on the reported clinical manifestations of G6PDd to provide a comprehensive overview of the situation in the GMS...
2017: BMJ Global Health
https://www.readbyqxmd.com/read/28954071/a-newly-validated-high-performance-liquid-chromatography-method-with-diode-array-ultraviolet-detection-for-analysis-of-the-antimalarial-drug-primaquine-in-the-blood-plasma
#5
Ana Paula Barbosa do Carmo, Manoella Borborema, Stephan Ribeiro, Ana Cecilia Xavier De-Oliveira, Francisco Jose Roma Paumgartten, Davyson de Lima Moreira
INTRODUCTION: Primaquine (PQ) diphosphate is an 8-aminoquinoline antimalarial drug with unique therapeutic properties. It is the only drug that prevents relapses of Plasmodium vivax or Plasmodium ovale infections. In this study, a fast, sensitive, cost-effective, and robust method for the extraction and high-performance liquid chromatography with diode array ultraviolet detection (HPLC-DAD-UV ) analysis of PQ in the blood plasma was developed and validated. METHODS: After plasma protein precipitation, PQ was obtained by liquid-liquid extraction and analyzed by HPLC-DAD-UV with a modified-silica cyanopropyl column (250mm × 4...
July 2017: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/28938907/integrative-analysis-associates-monocytes-with-insufficient-erythropoiesis-during-acute-plasmodium-cynomolgi-malaria-in-rhesus-macaques
#6
Yan Tang, Chester J Joyner, Monica Cabrera-Mora, Celia L Saney, Stacey A Lapp, Mustafa V Nural, Suman B Pakala, Jeremy D DeBarry, Stephanie Soderberg, Jessica C Kissinger, Tracey J Lamb, Mary R Galinski, Mark P Styczynski
BACKGROUND: Mild to severe anaemia is a common complication of malaria that is caused in part by insufficient erythropoiesis in the bone marrow. This study used systems biology to evaluate the transcriptional and alterations in cell populations in the bone marrow during Plasmodium cynomolgi infection of rhesus macaques (a model of Plasmodium vivax malaria) that may affect erythropoiesis. RESULTS: An appropriate erythropoietic response did not occur to compensate for anaemia during acute cynomolgi malaria despite an increase in erythropoietin levels...
September 22, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28883977/management-of-plasmodium-vivax-risk-and-illness-in-travelers
#7
EDITORIAL
J Kevin Baird
Malaria poses an exceptionally complex problem for providers of travel medicine services. Perceived high risk of exposure during travel typically prompts prescribing protective antimalarial drugs. Suppressive chemoprophylactic agents have dominated strategy for that practice for over 70 years. This broad class of therapeutic agents kills parasites after they emerge from the liver and attempt development in red blood cells. The dominance of suppressive chemoprophylaxis in travel medicine stems largely from the view of Plasmodium falciparum as the utmost threat to the patient - these drugs are poorly suited to preventing Plasmodium vivax and Plasmodium ovale due to inactivity against the latent liver stages of these species not produced by P...
2017: Tropical Diseases, Travel Medicine and Vaccines
https://www.readbyqxmd.com/read/28862132/the-complex-relationship-of-exposure-to-new-plasmodium-infections-and-incidence-of-clinical-malaria-in-papua-new-guinea
#8
Natalie E Hofmann, Stephan Karl, Rahel Wampfler, Benson Kiniboro, Albina Teliki, Jonah Iga, Andreea Waltmann, Inoni Betuela, Ingrid Felger, Leanne J Robinson, Ivo Mueller
The molecular force of blood-stage infection (molFOB) is a quantitative surrogate metric for malaria transmission at population level and for exposure at individual level. Relationships between molFOB, parasite prevalence and clinical incidence were assessed in a treatment-to-reinfection cohort, where P.vivax (Pv) hypnozoites were eliminated in half the children by primaquine (PQ). Discounting relapses, children acquired equal numbers of new P. falciparum (Pf) and Pv blood-stage infections/year (Pf-molFOB = 0-18, Pv-molFOB = 0-23) resulting in comparable spatial and temporal patterns in incidence and prevalence of infections...
September 1, 2017: ELife
https://www.readbyqxmd.com/read/28857064/implementation-of-g6pd-testing-and-primaquine-for-p-vivax-radical-cure-operational-perspectives-from-thailand-and-cambodia
#9
Suravadee Kitchakarn, Dysoley Lek, Sea Thol, Chantheasy Hok, Aungkana Saejeng, Rekol Huy, Nipon Chinanonwait, Krongthong Thimasarn, Chansuda Wongsrichanalai
Following progressive success in reducing the burden of malaria over the past two decades, countries of the Asia Pacific are now aiming for elimination of malaria by 2030. Plasmodium falciparum and Plasmodium vivax are the two main malaria species that are endemic in the region. P. vivax is generally perceived to be less severe but will be harder to eliminate, owing partly to its dormant liver stage (known as a hypnozoite) that can cause multiple relapses following an initial clinical episode caused by a mosquito-borne infection...
September 2017: WHO South-East Asia Journal of Public Health
https://www.readbyqxmd.com/read/28836792/galactose-anchored-gelatin-nanoparticles-for-primaquine-delivery-and-improved-pharmacokinetics-a-biodegradable-and-safe-approach-for-effective-antiplasmodial-activity-against-p-falciparum-3d7-and-in-vivo-hepatocyte-targeting
#10
Hitesh Kumar, Avinash Gothwal, Iliyas Khan, Kartik T Nakhate, Amit Alexander, Ajazuddin, Vineeta Singh, Umesh Gupta
Primaquine phosphate (PQ) is mainly used as a radical cure therapy to eradicate relapse of malaria at the liver stage, which is particularly caused by P. falciparum and P. vivax. In the present study, PQ-loaded galactosylated gelatin nanoparticles (Gel-LA-PQ-NPs) were formulated using a one-step desolvation technique. The mean particle size of Gel-LA-PQ-NPs was found to be 93.48 ± 6.36 nm with a zeta potential of 4.80 ± 0.20 mV having 69.90 ± 1.53% encapsulation efficiency. Electron microscopy demonstrated that the NPs were spherical in shape and uniformly distributed without any cluster formation...
October 2, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28820683/malaria-in-the-guangxi-zhuang-autonomous-region-in-china-a-twelve-year-surveillance-data-study
#11
Kangming Lin, Haiyan Wei, Weikang Jiang, Jun Li, Weiwei Zhang, Shujiao Wei, Yichao Yang, Yaming Huang, Xiangyang Feng, Hong Tu, Jun Feng
The incidence of an indigenous malaria, defined as malaria acquired by a local mosquito transmission, declined from 2004 to 2015 in the Guangxi Zhuang Autonomous Region. However, imported malaria, defined as malaria acquired from other endemic regions outside of China, has been increasing in the region, as in the rest of the country, particularly the disease caused by Plasmodium falciparum. A retrospective study was conducted to explore malaria-endemic characteristics in Guangxi during the 2004-2015 timeframe; a total of 2,726 confirmed malaria cases were reported, and the majority (90...
October 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28804661/imported-asymptomatic-bancroftian-filariasis-discovered-from-a-plasmodium-vivax-infected-patient-a-case-report-from-singapore
#12
Jean-Marc Chavatte, Roland Jureen
Human lymphatic filariasis is a vector-borne disease mainly caused by the parasitic nematode Wuchereria bancrofti and transmitted worldwide within the tropical and subtropical regions. Singapore was once endemic for bancroftian filariasis but recent reports are scarce and the disease is nearly forgotten. The case report presented here reports the incidental hospital laboratory finding of an asymptomatic microfilaremia in a relapsing Plasmodium vivax imported case during a malaria treatment follow-up appointment...
2017: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/28759593/proteogenomic-analysis-of-the-total-and-surface-exposed-proteomes-of-plasmodium-vivax-salivary-gland-sporozoites
#13
Kristian E Swearingen, Scott E Lindner, Erika L Flannery, Ashley M Vaughan, Robert D Morrison, Rapatbhorn Patrapuvich, Cristian Koepfli, Ivo Muller, Aaron Jex, Robert L Moritz, Stefan H I Kappe, Jetsumon Sattabongkot, Sebastian A Mikolajczak
Plasmodium falciparum and Plasmodium vivax cause the majority of human malaria cases. Research efforts predominantly focus on P. falciparum because of the clinical severity of infection and associated mortality rates. However, P. vivax malaria affects more people in a wider global range. Furthermore, unlike P. falciparum, P. vivax can persist in the liver as dormant hypnozoites that can be activated weeks to years after primary infection, causing relapse of symptomatic blood stages. This feature makes P. vivax unique and difficult to eliminate with the standard tools of vector control and treatment of symptomatic blood stage infection with antimalarial drugs...
July 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28750669/population-level-estimates-of-the-proportion-of-plasmodium-vivax-blood-stage-infections-attributable-to-relapses-among-febrile-patients-attending-adama-malaria-diagnostic-centre-east-shoa-zone-oromia-ethiopia
#14
Lemu Golassa, Michael T White
BACKGROUND: Malaria is ranked as the leading communicable disease in Ethiopia, where Plasmodium falciparum and Plasmodium vivax are co-endemic. The incidence of P. vivax is usually considered to be less seasonal than P. falciparum. Clinical cases of symptomatic P. falciparum exhibit notable seasonal variation, driven by rainfall-dependent variation in the abundance of Anopheles mosquitoes. A similar peak of clinical cases of P. vivax is usually observed during the rainy season. However, the ability of P...
July 27, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28749773/hemolytic-potential-of-tafenoquine-in-female-volunteers-heterozygous-for-glucose-6-phosphate-dehydrogenase-g6pd-deficiency-g6pd-mahidol-variant-versus-g6pd-normal-volunteers
#15
Ronnatrai Rueangweerayut, Germana Bancone, Emma J Harrell, Andrew P Beelen, Supornchai Kongpatanakul, Jörg J Möhrle, Vicki Rousell, Khadeeja Mohamed, Ammar Qureshi, Sushma Narayan, Nushara Yubon, Ann Miller, François H Nosten, Lucio Luzzatto, Stephan Duparc, Jörg-Peter Kleim, Justin A Green
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozygous for the Mahidol(487A) glucose-6-phosphate dehydrogenase (G6PD)-deficient variant versus G6PD-normal females, and with reference to primaquine. Six G6PD-heterozygous subjects (G6PD enzyme activity 40-60% of normal) and six G6PD-normal subjects per treatment group received single-dose tafenoquine (100, 200, or 300 mg) or primaquine (15 mg × 14 days)...
September 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28617860/increasing-prevalence-of-infectious-diseases-in-asylum-seekers-at-a-tertiary-care-hospital-in-switzerland
#16
Constantine Bloch-Infanger, Veronika Bättig, Jürg Kremo, Andreas F Widmer, Adrian Egli, Roland Bingisser, Manuel Battegay, Stefan Erb
OBJECTIVE: The increasing number of refugees seeking asylum in Europe in recent years poses new challenges for the healthcare systems in the destination countries. The goal of the study was to describe the evolution of medical problems of asylum seekers at a tertiary care centre in Switzerland. METHODS: At the University Hospital Basel, we compared all asylum seekers during two 1-year time periods in 2004/05 and 2014/15 concerning demographic characteristics and reasons for referrals and hospitalizations...
2017: PloS One
https://www.readbyqxmd.com/read/28615258/effect-of-a-package-of-health-and-nutrition-services-on-sustained-recovery-in-children-after-moderate-acute-malnutrition-and-factors-related-to-sustaining-recovery-a-cluster-randomized-trial
#17
RANDOMIZED CONTROLLED TRIAL
Heather C Stobaugh, Lucy B Bollinger, Sara E Adams, Audrey H Crocker, Jennifer B Grise, Julie A Kennedy, Chrissie Thakwalakwa, Kenneth M Maleta, Dennis J Dietzen, Mark J Manary, Indi Trehan
Background: Children who recover from moderate acute malnutrition (MAM) have high rates of relapse in the year after nutritional recovery. Interventions to decrease these adverse outcomes are needed to maximize the overall effectiveness of supplemental feeding programs (SFPs).Objective: We evaluated the effectiveness of a package of health and nutrition interventions on improving the proportion of children who sustained recovery for 1 y after MAM treatment. We further explored factors related to sustained recovery...
August 2017: American Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/28612497/pharmacotherapy-follow-up-role-in-active-malaria-surveillance-in-a-travel-medicine-centre-outside-the-transmission-area-in-brazil
#18
R S Pedro, P Brasil, A Pina-Costa, C R Machado, L S Damasceno, C T Daniel-Ribeiro, L Guaraldo
WHAT IS KNOWN AND OBJECTIVE: Malaria is a potentially severe disease, widespread in tropical and subtropical areas. Apart from parasite drug resistance, which receives the largest share of attention, several factors directly influence the response to antimalarial treatment such as incorrect doses, adverse drug events, lack of adherence to treatment, drug quality and drug-drug interactions. Pharmacotherapy follow-up can be used to monitor and improve the effectiveness of treatment, prevent drug-related problems and ensure patient safety...
June 13, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28526056/the-blood-schizonticidal-activity-of-tafenoquine-makes-an-essential-contribution-to-its-prophylactic-efficacy-in-nonimmune-subjects-at-the-intended-dose-200%C3%A2-mg
#19
REVIEW
Geoffrey Dow, Bryan Smith
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial being developed for malaria prophylaxis. It has been generally assumed that TQ, administered prophylactically, acts primarily on the developing exoerythrocytic stages of malaria parasites (causal prophylaxis), and that polymorphisms in metabolic enzymes thought to impact the activity of other 8-aminoquinolines also inhibit this property of TQ. Furthermore, it has been suggested that a diagnostic test for CYP2D6 metabolizer status might be required. In field studies in which metabolic status was not an exclusion criteria, TQ has been shown to exhibit similar prophylactic efficacy as blood schizonticidal drugs (mefloquine)...
May 19, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28446690/antimalarial-efficacy-of-mmv390048-an-inhibitor-of-plasmodium-phosphatidylinositol-4-kinase
#20
Tanya Paquet, Claire Le Manach, Diego González Cabrera, Yassir Younis, Philipp P Henrich, Tara S Abraham, Marcus C S Lee, Rajshekhar Basak, Sonja Ghidelli-Disse, María José Lafuente-Monasterio, Marcus Bantscheff, Andrea Ruecker, Andrew M Blagborough, Sara E Zakutansky, Anne-Marie Zeeman, Karen L White, David M Shackleford, Janne Mannila, Julia Morizzi, Christian Scheurer, Iñigo Angulo-Barturen, María Santos Martínez, Santiago Ferrer, Laura María Sanz, Francisco Javier Gamo, Janette Reader, Mariette Botha, Koen J Dechering, Robert W Sauerwein, Anchalee Tungtaeng, Pattaraporn Vanachayangkul, Chek Shik Lim, Jeremy Burrows, Michael J Witty, Kennan C Marsh, Christophe Bodenreider, Rosemary Rochford, Suresh M Solapure, María Belén Jiménez-Díaz, Sergio Wittlin, Susan A Charman, Cristina Donini, Brice Campo, Lyn-Marie Birkholtz, Kirsten K Hanson, Gerard Drewes, Clemens H M Kocken, Michael J Delves, Didier Leroy, David A Fidock, David Waterson, Leslie J Street, Kelly Chibale
As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-to-mouse transmission were achieved in the Plasmodium berghei mouse model...
April 26, 2017: Science Translational Medicine
keyword
keyword
65118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"